MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cusack, B.
Right arrow Articles by Kozikowski, A. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cusack, B.
Right arrow Articles by Kozikowski, A. P.

Pharmacological studies on novel neurotensin mimetics: discovery of a pharmacologically unique agent exhibiting concentration-dependent dual effects as antagonist and agonist

B Cusack, E Richelson, YP Pang, J Zaidi and AP Kozikowski

Neuropsychopharmacology Research, Mayo Foundation for Medical Education and Research, Jacksonville, Florida 32224.

We report the development of two novel neurotensin mimetics (mimics 1 and 2). These compounds were rationally designed and synthesized according to the multiple template approach. We present results of experiments designed to define their pharmacological profiles. In radioligand binding assays with murine neuroblastoma clone N1E-115, we determined the equilibrium dissociation constants for these compounds at the neurotensin receptor. The Kd values for mimic 1 and mimic 2 were 3.3 microM and 1.9 microM, respectively. Functionally, both mimetics antagonized the neurotensin-stimulated production of cGMP, with Kd values in the low micromolar range. Interestingly, mimic 2 displayed a dualistic pharmacological profile, which was concentration dependent. At doses in the 10-100 microM range, mimic 2 became a full agonist, stimulating cGMP production in N1E-115 cells with an EC50 value of 19 microM. Furthermore, mimic 1 did not antagonize the cGMP response elicited by mimic 2. When the neurotensin receptor was desensitized with a neurotensin receptor agonist, mimic 2 failed to stimulate significant cGMP production. We propose that mimic 2 binds to a higher affinity site when acting as an antagonist and binds to a lower affinity and different site when acting as an agonist. Thus, mimic 2 would appear to represent a unique pharmacological tool to characterize the neurotensin receptor and its diverse binding sites in N1E-115 cells.

Volume 44, Issue 5, pp. 1036-1040, 11/01/1993
Copyright © 1993 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Pharmacol. Rev.Home page
E. B. Binder, B. Kinkead, M. J. Owens, and C. B. Nemeroff
Neurotensin and Dopamine Interactions
Pharmacol. Rev., December 1, 2001; 53(4): 453 - 486.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
B. Cusack, K. Groshan, D. J. McCormick, Y.-P. Pang, R. Perry, C.-T. Phung, T. Souder, and E. Richelson
Chimeric Rat/Human Neurotensin Receptors Localize a Region of the Receptor Sensitive to Binding of a Novel, Species-specific, Picomolar Affinity Peptide
J. Biol. Chem., June 21, 1996; 271(25): 15054 - 15059.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y.-P. Pang, B. Cusack, K. Groshan, and E. Richelson
Proposed Ligand Binding Site of the Transmembrane Receptor for Neurotensin(8-13)
J. Biol. Chem., June 21, 1996; 271(25): 15060 - 15068.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1993 by the American Society for Pharmacology and Experimental Therapeutics